GAP President John Dwyer, on Lecanemab detailed results: “There is every reason for the Alzheimer’s community to have optimism today”

Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]

Read More…

First of its Kind Head-to-Head Study Comparing Leading Biomarkers for Detecting Alzheimer’s Disease Closes With Unprecedented Representation from Underrepresented Populations

The Global Alzheimer’s Platform Foundation (GAP) closed its ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, which is powered to measure more than 36 technologies’ effectiveness across three stages of Alzheimer’s disease, while drawing from all races and ethnic groups affected by the disease. WASHINGTON, DC (Nov. 15, 2022) — In 18 months, the Global […]

Read More…

Statement on Roche Announcement on Gantenerumab Attributed to John Dwyer, GAP Foundation President

The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of […]

Read More…

Global Alzheimer’s Platform Foundation (GAP) Supports New Bill from U.S. Representative Vern Buchanan

WASHINGTON, DC, Oct. 5, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and vigorously supports Congressmembers Vern Buchanan (R-FL) and Nanette Diaz Barragán (D-CA) for bringing forward a new bill to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries, including access to approved Alzheimer’s treatments. The bill — known as […]

Read More…

Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results

WASHINGTON, DC, Sept. 28, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s disease, marking an enormous milestone for millions of people living with Alzheimer’s disease. The positive trial results, released by Eisai Tuesday night, show that the novel drug helped slow cognitive decline […]

Read More…

South Texas Health Clinic Applauded for Advancing Diverse Representation in Alzheimer’s Clinical Trials, Surmounting Challenges

GAP-Net Site El Faro Health and Therapeutics in Texas’ Starr County continues working to connect the area’s predominantly Hispanic community with access to Alzheimer’s research and health care. Washington, D.C. — Today, Global Alzheimer’s Platform Foundation (GAP) John Dwyer applauded the work that Dr. James Falcon and the whole El Faro Health and Therapeutics team […]

Read More…

Global Alzheimer’s Platform Foundation and WCG Collaborate to Improve Access to Clinical Trials for Traditionally Underrepresented Communities

The new program will provide much-needed resources and workforce development opportunities for clinical trial sites challenged by a shortage of approved raters. WASHINGTON, DC, Aug.1 — The Global Alzheimer’s Platform Foundation® (GAP) and WCG announced a joint program today that will increase the availability of educational resources and training to support Alzheimer’s disease research. This will provide […]

Read More…

More Volunteers from Traditionally Underrepresented Communities Needed in Alzheimer’s Clinical Trials

Global Alzheimer’s Platform Foundation to present information about trial diversity at the Alzheimer’s Association International Conference. WASHINGTON, DC, July 27, 2022 — As a leading organization focused on increasing participant diversity in Alzheimer’s clinical trials, the Global Alzheimer’s Platform Foundation® (GAP) will present data at the Alzheimer’s Association International Conference® 2022 (AAIC®) to share information about its […]

Read More…

GAP Takes Alzheimer’s Clinical Trials On the Road to Remove Barriers to Access

Global Alzheimer’s Platform Foundation’s new mobile research site is taking Alzheimer’s clinical trials on the road to traditionally underrepresented communities. WASHINGTON, DC, July 14, 2022 — Today, Global Alzheimer’s Platform Foundation (GAP) announced the launch of a new mobile health site, which is hitting the road to reduce barriers to clinical trial participation. While more than six […]

Read More…